

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 September 2003 (12.09.2003)

PCT

(10) International Publication Number  
**WO 03/074023 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 9/00**, 31/485 (74) Agents: **MINOJA, Fabrizio** et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).
- (21) International Application Number: PCT/EP03/01962 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 26 February 2003 (26.02.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
02004786.6 1 March 2002 (01.03.2002) EP (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **CHIESI FARMACEUTICI S.p.A.** [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **DAVIES, Rebecca, Jaine** [GB/IT]; Via Palermo 26/A, I-43100 Parma (IT). **GANDERTON, David** [GB/IT]; Via Palermo, 26/A, I-43100 Parma (IT). **LEWIS, David, Andrew** [GB/IT]; Via Palermo 26/A, I-43100 Parma (IT). **MEAKIN, Brian, John** [GB/IT]; Via Palermo 26/A, I-43100 Parma (IT). **BRAMBILLA, Gaetano** [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). **FERRARIS, Alessandra** [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT).
- Published:**  
— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: AEROSOL FORMULATIONS FOR PULMONARY ADMINISTRATION OF MEDICAMENTS TO PRODUCE A SYSTEMIC EFFECT

(57) Abstract: The invention discloses an aerosol pharmaceutical composition comprising a medicament in solution in a mixture of a hydrofluoroalkane propellant and one or more co-solvents wherein the aerosol liquid droplets delivered on actuation of the inhaler have a particle size comprised between 0,5 µm and 2.5 µm, with a mass median aerodynamic diameter of about 1-2 µm and wherein the fine particle fraction is at least 30%.

WO 03/074023 A1

**AEROSOL FORMULATIONS FOR PULMONARY ADMINISTRATION  
OF MEDICAMENTS TO PRODUCE A SYSTEMIC EFFECT**

**Field of the invention**

This invention relates to aerosol solution formulations comprising a medicament, a propellant, one or more co-solvents and optionally other additives commonly used in this kind of formulations.

5       **Background of the invention**

Many pharmaceutically active compounds currently used in clinical practice and exhibiting problems of administration and/or absorption by the oral, parenteral or transdermal administration could take advantage from a pulmonary delivery, aimed at obtaining a systemic effect.

10       Pharmaceutically active compounds could be administered to the respiratory tract by using pressurised metered dose inhalers (pMDIs). PMDIs use a propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol.

15       The formulation can be a solution or a suspension. Solution formulations, in comparison to suspensions, do not present problems of physical stability of the suspended particles and could therefore guarantee a higher dose uniformity and reproducibility.

20       As far as the propellant is concerned, hydrofluoroalkanes [(HFAs) known also as hydro-fluoro-carbons (HFCs)] would be mandatory propellants as chlorofluorocarbons (known also as Freons or CFCs), which were for many years the preferred aerosol propellants for pharmaceutical use, have been banned in view of their environmental impact.

25       In particular, 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) have been acknowledged to be the best candidates for non-CFC propellants and a number of pharmaceutical aerosol

formulations using such HFA propellants have been disclosed.

### Disclosure of the invention

The aim of providing solution formulations in a HFA propellant for aerosol delivery of medicaments is to give a prompt systemically active dose  
5 of said medicament *via* the respiratory tract.

Hereinafter the term medicament is used to define any pharmaceutical active compound which could take advantage from a pulmonary delivery so as to produce a systemic therapeutic effect.

In order to provide therapeutically useful plasma levels, a therapeutic  
10 concentration of medicament and an efficient aerosol delivery should be achieved.

An important parameter for an efficient aerosol delivery to produce a systemic therapeutic effect is the particle size distribution in the aerosol cloud. When the formulation is in the form of suspension, the particle size of the  
15 cloud is dominated by the particle size of the suspended drug, defined by the milling/micronization process.

When the formulation is in the form of solution, the volumetric contribution of suspended drug particles is absent and much finer liquid droplets clouds, largely defined by the drug concentration in the solution, are  
20 generated.

The size of the particles provided by the pMDI, is normally expressed as mass median aerodynamic diameter (MMAD). The particle size of choice of aerosol medicaments for the treatment of bronchopulmonary diseases is usually of approximately 3  $\mu\text{m}$ . The preferred diameter of the aerosol particles  
25 or droplets is comprised between 0.5 and 5  $\mu\text{m}$ .

When the medicament is delivered to the lungs through an aerosol metered dose inhaler so as to produce a systemic effect, the particles should be small enough to be delivered to the lungs and to be absorbed into the

bloodstream upon inhalation, i.e. of a size advantageously comprised between about 0.5  $\mu\text{m}$  and 2.5  $\mu\text{m}$  (MMAD of about 1-2  $\mu\text{m}$ ). Particles smaller than 0.5  $\mu\text{m}$  are indeed not therapeutically useful as they are exhaled.

5 The aerosol solution formulations offer the advantage of being homogeneous with the active ingredient and with the excipients which are completely dissolved in the propellant vehicle or in the mixtures thereof with suitable co-solvents such as ethanol. Solution formulations also obviate physical stability problems associated with suspension formulations, thus assuring reproducible dosage.

10 Furthermore, when a systemic effect is required, as in the case of the invention, aerosol solution formulations offer the advantage that much finer clouds, largely defined by the drug concentration in the solution, are generated and the finer clouds give more extensive deposition in the lung periphery.

15 When a medicament is slightly soluble in HFA propellants such as HFA 134a and HFA 227 or in their mixture, the use of a solvent, generally ethanol is necessary.

20 When a medicament is very slightly soluble in the propellant large amounts of ethanol are required. A large amount of ethanol, in turn, increases, proportionally to its concentration, the size of the aerosol droplets leaving the actuator orifice. The larger size droplets extensively deposit into the oropharyngeal tract to the detriment of the drug dose fraction which penetrates into the lower airways (respirable fraction). A poorly respirable fraction is unlikely to give the medicament serum levels necessary to produce a therapeutic effect.

25 Moreover, an increased amount of ethanol in the formulation means also an increased amount of residual water. Whereas an amount of water up to 10% w/w, preferably comprised between 0.5 and 8% w/w and more preferably between 0.5 and 6% may be in some cases useful to improve the solubility of

the medicament in the propellant/co-solvent system, in other cases the presence of water could enhance the degradation of the medicament and could be detrimental to the physical stability of the formulation giving rise to a non-homogeneous system.

5        It would be advantageous to provide a formulation for pulmonary delivery to be used with pressurised metered dose inhalers, which is chemically and physically stable and capable of providing, on actuation, a suitable fine particle dose (FPD) and a fine respirable fraction (FPF) providing early therapeutic plasma levels of a medicament. The fine particle dose or  
10    respirable dose is the amount of active particles of size less than  $4.7\text{ }\mu\text{m}$  and the fine particle fraction or respirable fraction is the ratio between the respirable dose and the dose delivered on actuation of the inhaler. The respirable fraction should be at least 30%, preferably more than 40%, even more preferably higher than 50% of the delivered dose.

15        It would also be highly advantageous to provide formulation whose delivered dose is highly reproducible after repeated administrations from the pMDI.

      Since a high systemic exposure of the aerosol particles would, in this case, be of benefit, it would be even more advantageous to provide a  
20    formulation wherein the composition of the whole solvent system has been adjusted in order to allow the generation of aerosol particles which could then allow a deep lung penetration, at the same time minimizing the amount of very small particles ( $\leq 0.5\text{ }\mu\text{m}$ ) which would be exhaled.

      The invention provides a solution to said problems by means of solution  
25    formulations comprising a medicament, an HFA propellant and optionally one or more co-solvents. Said solutions are chemically stable for an adequate time and capable of providing, on actuation, a respirable fraction giving rise to onset-hastened therapeutic plasma levels of the medicament.

The preferred co-solvents are lower alkyl (C<sub>1</sub>-C<sub>4</sub>) alcohols, polyols, polyalkylene glycols and their combinations.

Ethanol is particularly preferred.

Other suitable co-solvents are (poly)alkoxy derivatives including  
5 polyalkoxy alcohols, in particular 2-(2-ethoxyethoxy) ethanol (available under the trademark Transcutol®).

Further (poly)alkoxy derivatives include polyoxyalkyl ethers and esters, such as polyoxyethylene ethers or esters. The preferred polyoxyethylene ethers and esters are polyoxyethylene alkyl ethers, polyoxyethylene sorbitan  
10 fatty acid esters and polyoxyethylene stearates.

As a co-solvent a fatty acid alkyl ester can be also utilised. The preferred fatty acid alkyl esters are ethyl oleate, isopropyl myristate and isopropyl palmitate.

According to a preferred embodiment, the invention provides a  
15 pharmaceutical composition comprising a medicament, a HFA propellant, an amount of ethanol up to 30%, preferably up to 20%, more preferably up to 10% w/w and a co-solvent with a higher polarity than ethanol in amount from 0.2% to 10% w/w, preferably from 0.5 to 10% w/w, more preferably from 0.5 to 6% w/w, even more preferably from 1 to 2% w/w.

20 The polarity may be quantified, and thus compared, in terms of a dielectric constant, or by using Maxwell's equation to relate dielectric constant to the square of the refractive index - the refractive index of materials being readily measurable or obtainable from the literature. Alternatively, the polarity of co-solvents may be measured using the Kauri-  
25 butanol value for estimation of solvent power. The protocol is described in ASTM Standard: Designation 1133-86.

The addition of a co-solvent with a higher polarity than ethanol allows reduction in the ethanol amount allowing the modulation of the particle size of

the produced aerosol droplets.

Co-solvents with a higher polarity than ethanol can be preferably selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>) alcohol, polyols or polyalkylene glycols.

The preferred polyols include propylene glycol and glycerol and the  
5 preferred polyalkylene glycol is polyethylene glycol.

Among the co-solvents with a higher polarity than ethanol water is to be considered comprised. The amount of water, when present, is up to 10% w/w, preferably comprised between 0.5 and 8% w/w and more preferably between 0.5 and 6%.

10 According to an even more preferred embodiment, the invention provides a pharmaceutical composition consisting essentially of a medicament, a HFA propellant, optionally ethanol in amounts comprised between 2 and 30% w/w, preferably between 5% and 20% w/w, more preferably up to 10% w/w and optionally a co-solvent. Advantageously, the  
15 amount of the active ingredient is of at least 0.01% w/v and preferably comprised between 0.1 and 1.0% w/v.

Small amounts of ethanol and of a co-solvent are useful also when the medicament is fully soluble in the propellant.

It has been indeed found that, although the solvent is not needed to  
20 dissolve the medicament in the propellant, a small amount of ethanol (preferably comprised around 5-8% w/w, more preferably around 5% w/w), influencing the deposition characteristics, may make systemic delivery easier, since ethanol helps the reduction of the amount of very small particles (<0.5 µm) which would be exhaled due to a short residency time in the lung.  
25 Moreover, ethanol reduces the deposition of discharged material on the inhaler actuator orifice, so improving the dose reproducibility after repeated administrations by keeping 'clean' the actuator orifice.

Due to this "cleaning" effect of ethanol generally the use of surface

active agents or "surfactants" as valve lubricants is not necessary.

In certain cases, however, the formulation may optionally contain small amounts of additional components such as surfactants or other additives which are preservatives, buffers, antioxidants, radical quenchers, sweeteners and  
5 taste masking agents.

The preferred organic surfactant is selected from oleyl alcohol, sorbitan trioleate, sorbitan mono-oleate, sorbitan monolaurate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan mono-oleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether,  
10 lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropylene, oleic acid, synthetic lecithin, diethylene glycol dioleate, tetrahydrofurfuryl oleate, ethyl oleate, isopropyl myristate, glyceryl mono-oleate, glyceryl monostearate, glyceryl monoricinoleate, cetyl alcohol, stearyl alcohol, cetyl pyridinium chloride, olive oil, glyceryl monolaurate, corn oil,  
15 cotton seed oil or sunflower seed oil.

According to a further aspect, the invention provides a method of filling an aerosol inhaler with a composition of the invention, the method comprising:

- 20 (a) weighing the required quantity of active ingredient into the can or vial;
- (b) adding the appropriate volume of ethanol and of an additional co-solvent, if required;
- (c) crimping with valves and gassing;
- (d) adding a propellant containing a hydrofluoroalkane (HFA).

25 Any medicament which can be administered by inhalation as aerosol, capable of being solubilized in an HFA/ethanol/co-solvent system and of being absorbed into the blood stream via the lung, may be used in the aerosol composition of the invention. Examples of said medicaments are



cyclooxygenase-, mast cell-, lipoxigenase- and proteolytic enzyme - inhibitors, arachidonic acid-, leukotriene-, thromboxane-, sodium/potassium channel-, neurokinin-, tachykinin-, bradykinin-, muscarine-, histamine-, phosphodiesterase- and selectin - antagonists, potassium channel blockers, anti-infective agents, antibiotics, pentamidine, cytostatics, fungistatics, free-radical scavengers, vitamins, hormones, immunostimulants, immunosuppressants, heparin, antidiabetics, analgesics, hypnotics and the like, for example:

- leukotriene antagonists such as iralukast, zafirlukast and pranlukast,
- 10 - a lipoxygenase inhibitor such as zileuton,
- sodium channel antagonists such as amiloride, potassium channel antagonists, bimakalim,
- arachidonic acid antagonists such as 2-benzoxazoline,
- histamine receptor antagonists such as epinastine, azelastine,
- 15 cinnarizine, cetirizine, mizolastine, mequitamium, chlorpheniramine, astemizole, terfenadine and fenoxfenadine,
- antimigrain agents such as ergot alkaloids methysergide, ergotamine, serotonin, sumatriptan, zolmitriptan, cyclandelate etc.,
- analgesics such as fentanyl, morphine, buprenorphine, opium,
- 20 heroin, nalbuphine, pentazocine, oxycodone, tramadol, pethidine, tilidine, methadone, nefopam, dextropropoxyphene, piritramide, etc.,
- antiemetics such as bromopride, domperidone, metoclopramide, triethylperazine, trifluoropromazine, meclozine, chlorphenoxamine, dimenhydrinate etc.,
- 25 - antibiotics such as penicillins (e.g. azlocillin), cephalosporins (e.g. cefotiam or ceftriaxone), carbapenems, monobactams, aminoglycosides (e.g. streptomycin, neomycin, gentamycin, amikacin or tobramycin), quinolones (e.g. ciprofloxacin), macrolides

- (e.g. erythromycin), nitroimidazoles (e.g. tinidazol), lincosamide (e.g. clindamycin), glycopeptides (e.g. vancomycin), polypeptides (e.g. bacitracin), mupirocin etc.,
- vitamins and free-radical scavengers such as vitamin A, B, C, D or E, catalase, superoxide dismutase, reduced glutathione etc.,
  - antidiabetics such as glibenclamide, glipizide, gliclazide, glimepiride, troglitazone etc.,
  - hypnotics such as benzodiazepines, piperidonediones, antihistaminics etc.,
  - neuroleptics, antidepressants and anticonvulsants such as benzodiazepines, phenothiazines, butyrophenones, sulpiride, hydantoins, barbiturates, succinimides, carbamazepine etc.,
  - systemically active drugs such as, for example, isosorbide dinitrate, isosorbide mononitrate, apomorphine and cannabinoids,
  - antiinflammatory agents,
  - hormones and their synthetic analogues such as androgens (e.g. testosterone), antioestrogens, LHRH, leuprolide acetate, calcitonin, parathyrin, somatotropin, oxytocin, prolactin, glucagon, erythropoietin, atriopeptin, melanotropin, thyrotropin, gonadotropin, vasopressin, insulin, etc.,
  - potency agent such as alprostadil,
  - cytostatics such as nitrogen mustard derivatives (such as ifosfamide), N-Nitrosourea derivatives (e.g. lomustin), purine and pyrimidine bases antagonists (e.g. fluorouracil), platinum complexes (e.g. carboplatin), anthracyclines (e.g. doxorubicin), podophylline derivatives (e.g. podophyllotoxin).

Although the preferred medicaments of the invention are those usually not administered as a pulmonary aerosol, the aerosol solution formulations of

the invention can be advantageously applied also to compounds already utilised in inhalation compositions, for instance a beta-mimetic such as salmeterol; a corticosteroid preferably selected from triamcinolone, ciclesonide, fluticasone and mometasone; an anticholinergic such as  
5 oxitropium bromide and tiotropium bromide; a mast cell inhibitor such as cromoglycic acid, nedocromil etc.

The high efficiency cloud generation allows to prepare formulations containing a medicament with a reduced nominal dose and a larger percentage of clinically useful medicament deposition with respect to the reference  
10 composition (FPF of at least 30%, preferably higher than 40%, even more preferably more higher than 50% of the delivered dose) and with defined particle size targeting specific areas of the lungs.

Said medicaments can optionally be used in the form of their esters, isomers, enantiomers or racemates and, in the case of acids or bases, as such or  
15 in the form of their pharmaceutically acceptable salts.

Advantageously, the concentration of the active ingredient is at least 0.01% w/v, preferably at least 0.05% w/v, more preferably between 0.1% w/v and 1.0% w/v, even more preferably at least 1.0% w/v.

It is preferable that the formulation is suitable for delivering a  
20 therapeutic amount of the active ingredient in one or two actuations. Advantageously the formulation will be suitable for delivering a therapeutic dose of at least 25 µg/dose, preferably between 50 and 500 µg/dose. By "therapeutic dose" it is meant the amount of active ingredient delivered by a single actuation of the inhaler able to produce a pharmacodynamic effect.

25 The formulations of the invention could be filled into cans suitable for delivering pharmaceutical aerosol formulations. Certain medicaments are subject to enhanced chemical degradation when stored in contact with the standard metal container usually made of aluminium. In these cases the

formulations will be filled preferably into cans having part or all of the internal surfaces made of anodised aluminium, stainless steel or lined with an inert organic coating. Examples of preferred coatings are epoxy-phenol resins, perfluoroalkoxyalkane, perfluoroalkoxy alkylene, perfluoroalkylenes such as  
5 polytetrafluoro-ethylene, fluorinated-ethylene-propylene, polyether sulfone and a copolymer fluorinated-ethylene-propylene polyether sulfone. Other suitable coatings could be polyamide, polyimide, polyamideimide, polyphenylene sulfide or their combinations.

To further improve the stability, cans having a rolled-in rim and  
10 preferably a part or full rollover rim are used.

The formulation is actuated by a metering valve capable of delivering a volume of between 25  $\mu$ l and 100  $\mu$ l.

The choice of the metering valve and type of gasket will be made according the knowledge of the person skilled in the art. The gasket may  
15 comprise any suitable elastomeric material such as low density polyethylene, EPDM, chloroprene and TPE.

Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example from Valois, France, Bepak plc, UK and 3M, Neotechnic Ltd, UK.

20 For reasons of chemical stability of the medicament in solution, it is preferred in some cases that the internal surfaces of metal valve components in contact with the formulation are coated with an inert material.

The currently used valve actuators with orifice diameter from 0.20 to 0.50 mm (and in particular 0.22, 0.33, 0.42 and 0.45 mm) can be generally  
25 used with the aerosol formulations of the invention. When large amounts of ethanol are required to dissolve the medicament, so as to obtain aerosol clouds with an optimal respirable fraction, valve actuators provided with orifice diameters comprised between 0.10-0.20 mm (and in particular 0.12, 0.14,

0.16, 0.18 mm) are advantageously used.

These kinds of orifices can be prepared according to the EP application n° 01 130521.6 in the Applicant's name.

In some cases, in order to stabilise the medicament in solution, it would  
5 be necessary to provide aerosol solutions with a specific apparent pH, which can be determined by the skilled in the art according to WO 01/894080.

The hydrofluorocarbon propellant is preferably selected from the group of HFA 134a, HFA 227 and mixtures thereof.

The co-solvent may include one or more solvents and in this case their  
10 ratio is a critical factor for an efficient aerosolization. The selection of said ratios may be anyhow made by the skilled in the art on the basis of the chemico-physical characteristics of the considered medicament.

The preferred co-solvents are usually alcohols such as ethanol, propanol, propylene glycol, polyethylene glycol, glycerol and their mixture in  
15 a total amount up to 30% w/w, preferably up to 25% w/w, more preferably up to 20% w/w.

Another useful co-solvent in some kinds of formulations is water.

Advantageously, the droplets size is between about 0.5  $\mu\text{m}$  and 2.5  $\mu\text{m}$ , corresponding to a MMAD of about 1-2  $\mu\text{m}$ .

#### 20 Preparation of HFA Solution pMDIs

The assembly of the pMDI cans was carried out using hand operated crimping and filling equipment. Formulations were prepared by accurately weighing the required quantity of drug into the can or vial. The appropriate volume of ethanol and the other co-solvent if required in the formulation, was  
25 then added. The valve was crimped onto the vial/can and the assembled vial/can was ultra-sonicated for approximately 10 minutes. The HFA propellant was filled through the valve and the pMDI was ultra-sonicated for a further 10 minutes. In the case of formulations that contained drug and

propellant only the pMDI was ultra-sonicated once, after the propellant had been added. Final compositions were calculated as percentage w/v for the active ingredient and as percentage w/w for the co-solvents.

#### **Solubility Studies**

- 5 All solubility investigations were conducted in plastic coated glass pMDI vials fitted with continuous spray valves. Once produced the medicament-HFA solution pMDIs were stored in refrigerator at 4°C ( $\pm 0.1^\circ\text{C}$ ). The pMDI vials were removed periodically and the vials assessed visually with the aid of a polarized light unit for crystal growth.

#### **Cascade Impaction Studies**

- 10 All impaction studies were conducted with formulations contained in cut edge anodised aluminium cans fitted with 50  $\mu\text{l}$  or 100  $\mu\text{l}$  valves. The studies were carried out using an Andersen Cascade Impactor (ACI) fitted with a USP XXII metal throat entry port.
- 15 The ACI was operated at a flow rate of  $28.3 \pm 2 \text{ l min}^{-1}$ . The HFA solution formulations were discharged into the ACI through actuators having an orifice diameter from 0.14 to 0.45 mm. Deposition of the drug on each ACI plate was determined by high pressure liquid chromatography (HPLC).

- MMAD values and corresponding geometric standard deviation (GSD) were calculated from plots of the cumulative percentage undersize of drug collected on each ACI plate (probit scale), against the upper cut off diameter for each respective ACI plate (log10 scale).

- The following parameters were determined: the metered dose, which is the sum of the dose delivered through the Andersen apparatus plus the active ingredient residue deposited on the device actuator; the cumulative amount of active particles deposited on the various ACI stages; the amount on the actuator; the amount in the adaptor and in the throat (adp/throat); the fine particle dose or respirable dose (FPD) which is the amount of particles

deposited on stages 3 to filter of the ACI and corresponds to the amount of particles of size less than 4.7  $\mu\text{m}$ ; the fine particle fraction or respirable fraction which is the ratio between the respirable dose and the dose delivered ex-actuator.

5        Examples of formulations according to the invention comprise:

- apomorphine esters in a HFA propellant selected from HFA 134a, HFA 227 and their mixtures and a co-solvent selected from an alcohol, a polyol and their mixtures. In a particular embodiment the formulation comprises up to 1% w/v diisobutyl apomorphine, up to 5% w/w ethanol, from 0 to 0.1% w/w glycerol and HFA 134a,
- leuprolide acetate in a HFA propellant selected from HFA 134a, HFA 227 and their mixtures and a cosolvent selected from an alcohol, water and their mixtures. In a particular embodiment the formulation comprises up to 0.26% w/v leuprolide acetate, from 15 to 30% w/w ethanol, from 2 to 5% w/w water and HFA 134a.

### Example 1

#### Solubility studies of diisobutyl apomorphine, aerosol delivery characteristics and stability of its corresponding pMDI formulations

##### Solubility studies

20        The solubility of diisobutyl apomorphine was investigated by producing pMDI formulations at various percentages of ethanol in HFA 134a or in HFA 227.

The results showed that formulations containing up to 1% w/v diisobutyl apomorphine are soluble in HFA 134a or HFA 227.

##### Aerosol delivery characteristics studies

25        0.5% and 1% w/v (250  $\mu\text{g}$  or 500  $\mu\text{g}/50 \mu\text{l}$  respectively) diisobutyl apomorphine HFA 134a solution formulations containing 5% w/w ethanol and 0.1% w/w glycerol were produced. The cans were provided with actuators

with an orifice diameter of 0.22 mm.

Two ACI deposition determinations were performed with each formulation. Twenty shots were discharged into the ACI.

The diisobutyl apomorphine formulations prepared according to the invention presented a MMAD of about 2.0  $\mu\text{m}$ , a fine particle fraction (FPF) of at least 70-75%, whereas the amount of active particles of sizes included in the range from 0.43 to 3.3  $\mu\text{m}$  was of at least of 60%.

#### Stability study

A stability study on a formulation prepared according to the Example 1 was initiated storing coated aluminum cans upright and inverted at 25°C.

The recovery of diisobutyl apomorphine was determined by HPLC.

At six months evaluation the recovery of the active ingredient was excellent and minimal degradation occurred. There was no significant difference between those cans stored upright and inverted.

#### Example 2

#### Solubility studies of leuprolide acetate, aerosol delivery characteristics and stability of its corresponding pMDI formulations

##### Solubility studies

The solubility of leuprolide acetate was investigated by producing pMDI formulations at various percentages of ethanol and water in HFA 134a or in HFA 227.

The results showed that formulations containing up to 0.26% w/v leuprolide acetate are soluble in ethanol, water, HFA 134a systems.

When water was added a significant increase of leuprolide acetate solubility within ethanol/HFA 134a systems was obtained.

##### Aerosol delivery characteristics studies

0.04% w/v (40  $\mu\text{g}/100 \mu\text{l}$ ) leuprolide acetate HFA 134a solution formulation containing 15% w/w ethanol and 2% w/w water was produced.



The cans were provided with actuators with an orifice diameter of 0.14 mm.

Two ACI deposition determinations were performed with the formulation. Ten shots were discharged into the ACI.

5 The leuprolide acetate formulation prepared according to the invention presented a MMAD of about 1.0  $\mu\text{m}$ , a fine particle fraction (FPF) of at least 72%, whereas the amount of active particles of sizes included in the range from 0.43 to 3.3  $\mu\text{m}$  was of at least of 61%.

Another HFA 134a solution formulation containing 0.08% w/v (80  $\mu\text{g}/100\text{ }\mu\text{l}$ ) leuprolide acetate, 18% w/w ethanol and 3% w/w water was  
10 produced. The cans were provided with actuators with an orifice diameter of 0.14 mm.

Two ACI deposition determinations were performed with the formulation. Ten shots were discharged into the ACI.

15 The leuprolide acetate formulation prepared according to the invention presented a MMAD of about 1.3  $\mu\text{m}$ , a fine particle fraction (FPF) of at least 59%, whereas the amount of active particles of sizes included in the range from 0.43 to 3.3  $\mu\text{m}$  was of at least of 52%.

#### Stability Studies

20 Stability studies on leuprolide 100  $\mu\text{g}/50\text{ }\mu\text{l}$  HFA 134a pMDIs containing 30% w/w ethanol and 5% w/w water was initiated storing coated aluminum cans upright and inverted at 25°C.

The leuprolide acetate content was determined by HPLC.

Excellent stability was observed over the six-month stability study.

CLAIMS

1. An aerosol pharmaceutical composition comprising a medicament solution in a mixture of a hydrofluoroalkane propellant and one or more co-solvents wherein the aerosol liquid droplets delivered on actuation of the inhaler have a particle size comprised between 0.5  $\mu\text{m}$  and 2.5  $\mu\text{m}$ , with a mass median aerodynamic diameter of about 1-2  $\mu\text{m}$  and wherein the fine particle fraction is at least 30%.
2. A pharmaceutical formulation according to claim 1 characterized in that the concentration of the medicament is at least 0.01 w/v.
3. A pharmaceutical formulation according to claim 1 to 2, characterized in that the concentration of the medicament is at least 0.05% w/w.
4. A pharmaceutical formulation according to claims 1-3, wherein the propellant includes one or more HFAs selected from HFA 134a and HFA 227.
5. A pharmaceutical formulation according to claims 1-4, wherein the co-solvent is ethanol in an amount up to 30% w/w.
6. A pharmaceutical formulation according to claims 1-5, wherein the co-solvent is selected from ethanol, a lower alkyl ( $\text{C}_1\text{-C}_4$ ) alcohol, a polyol or a polyalkylene glycol and their combinations.
7. A pharmaceutical formulation according to claim 6 wherein polyols are selected from glycerol and propylene glycol and the polyalkylene glycol is polyethylene glycol.
8. A pharmaceutical formulation according to claims 1-5, wherein the co-solvent is a (poly)alkoxy derivative selected from polyalkoxy alcohols and polyoxyalkyl ethers and esters.
9. A pharmaceutical formulation according to claim 8, wherein the polyalkoxy alcohol is Transcutol®.
10. A pharmaceutical formulation according to claim 8, wherein the

polyoxyalkyl ethers and esters are selected from polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters and polyoxyethylene stearates.

11. A pharmaceutical formulation according to claims 1-5, wherein the co-solvent comprises a fatty acid alkyl ester selected from ethyl oleate, isopropyl myristate and isopropyl palmitate.
12. A pharmaceutical formulation according to claims 1-6 wherein the co-solvent comprises up to 10% w/w of water.
13. A pharmaceutical formulation according to any preceding claim, wherein the fine particle fraction is at least 40%.
- 10 14. A pharmaceutical formulation according to any preceding claim, wherein the fine particle fraction is at least 50%.
15. An aerosol inhaler containing a formulation as claimed in any of claims 1 to 14, wherein the valve actuator has an orifice diameter from 0.20 to 0.50 mm.
- 15 16. An aerosol inhaler containing a formulation as claimed in any of claims 1 to 14, wherein the valve actuator has an orifice diameter from 0.10 to 0.20 mm.

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/01962

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K9/00 A61K31/485

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 326 334 A (CHIESI FARMACEUTICI, IT) 23 December 1998 (1998-12-23) page 12, line 24 -page 13, line 2 page 13, line 4 page 14, line 11 - line 19 examples	1-8, 12-16
X	GB 2 354 007 A (GLAXO GROUP LTD) 14 March 2001 (2001-03-14) examples page 3, line 5 - line 10 page 5, line 11 - line 19 page 6, line 11 - line 14 page 7, line 14 - line 25 page 11, line 5 - line 15 figure 12 page 18 -page 19	1-8, 12-16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

25 July 2003

Date of mailing of the international search report

01/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Rankin, R

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/01962

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 24420 A (BIOLOGAN IRELAND LTD.) 11 June 1998 (1998-06-11) page 2, line 21 -page 3, line 6 page 5, line 1 - line 18 page 6, line 9 - line 20 page 8, line 12 - line 17 page 7, line 12 examples claims -----	1,3-11
X	WO 00 30608 A (CHIESI FARMACEUTICI, IT) 2 June 2000 (2000-06-02) examples page 7, line 8 -page 8, line 14 -----	1-8, 10-13
X	WO 01 49350 A (CHIESI FARMACEUTICI, IT) 12 July 2001 (2001-07-12) examples -----	1-7, 12-16
X	WO 01 62227 A (CHIESI FARMACEUTICI, IT) 30 August 2001 (2001-08-30) page 6, line 24 -page 7, line 1 page 10, line 18 - line 21 examples -----	1,3,4,6, 7,12-16
X	WO 01 66089 A (GW PHARMA LTD., GB) 13 September 2001 (2001-09-13) page 5, line 24 - line 29 page 6, line 16 - line 26 page 7, line 10 - line 20 example 4 claims 3,8,10-16,24,25 -----	1,3-11
A	WO 01 74358 A (TAP HOLDINGS INC., USA) 11 October 2001 (2001-10-11) examples page 7, line 17 -page 8, line 18 page 9, line 23 - line 27 -----	1-16

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/01962

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
GB 2326334	A	23-12-1998	AT 222751 T	15-09-2002
			AU 729966 B2	15-02-2001
			AU 8626298 A	30-12-1998
			BG 63906 B1	30-06-2003
			BG 103221 A	30-09-1999
			BR 9805993 A	31-08-1999
			CN 1229355 T	22-09-1999
			CZ 9900462 A3	14-07-1999
			DE 69807420 D1	02-10-2002
			DE 69807420 T2	08-05-2003
			DK 920302 T3	23-12-2002
			EA 1259 B1	25-12-2000
			EE 9900055 A	16-08-1999
			WO 9856349 A1	17-12-1998
			EP 1219293 A2	03-07-2002
			EP 0920302 A1	09-06-1999
			ES 2182351 T3	01-03-2003
			HR 980317 A1	30-04-1999
			HU 0001339 A2	28-09-2000
			IT MI971798 A1	28-01-1999
			JP 2000516965 T	19-12-2000
			NO 990594 A	13-04-1999
			NZ 334149 A	28-07-2000
			PL 331531 A1	19-07-1999
			PT 920302 T	29-11-2002
			SI 920302 T1	31-12-2002
			SK 17699 A3	12-07-1999
			TR 9900288 T1	21-09-1999
			US 6264424 B1	24-07-2001
			US 2001031244 A1	18-10-2001
			ZA 9805136 A	07-01-1999
GB 2354007	A	14-03-2001	AU 7026800 A	17-04-2001
			CA 2317999 A1	11-03-2001
			EP 1143930 A2	17-10-2001
			FR 2798290 A1	16-03-2001
			FR 2820322 A1	09-08-2002
			WO 0119342 A2	22-03-2001
			IT RM20000491 A1	12-03-2001
			JP 2003509359 T	11-03-2003
			US 2003086876 A1	08-05-2003
			US 6479035 B1	12-11-2002
WO 9824420	A	11-06-1998	AU 726510 B2	09-11-2000
			AU 5402898 A	29-06-1998
			EP 1011646 A1	28-06-2000
			WO 9824420 A1	11-06-1998
			IE 970858 A2	12-08-1998
			JP 2001505171 T	17-04-2001
			NO 992677 A	15-07-1999
			NZ 336049 A	29-09-2000
			US 6413496 B1	02-07-2002
			ZA 9710923 A	02-09-1998
WO 0030608	A	02-06-2000	IT MI982559 A1	25-05-2000
			IT MI991712 A1	30-01-2001
			AU 1556300 A	13-06-2000
			BG 105532 A	31-12-2001

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/01962

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0030608	A	BR 9916868 A CA 2352484 A1 CN 1328445 T CZ 20011834 A3 DE 29923839 U1 EE 200100276 A WO 0030608 A1 EP 1131051 A1 HU 0104411 A2 JP 2002530156 T NO 20012516 A PL 348717 A1 SK 7042001 A3 TR 200101441 T2 US 2003089369 A1	06-11-2001 02-06-2000 26-12-2001 12-12-2001 01-03-2001 16-12-2002 02-06-2000 12-09-2001 28-03-2002 17-09-2002 23-07-2001 03-06-2002 06-11-2001 21-08-2001 15-05-2003
WO 0149350	A 12-07-2001	IT MI20000010 A1 AU 2512801 A BR 0107730 A CA 2396273 A1 CZ 20022331 A3 WO 0149350 A1 EP 1244487 A1 HU 0300405 A2 SK 9482002 A3	09-07-2001 16-07-2001 25-02-2003 12-07-2001 13-11-2002 12-07-2001 02-10-2002 28-06-2003 08-10-2002
WO 0162227	A 30-08-2001	IT MI20000312 A1 AU 4645001 A BR 0108584 A CA 2400691 A1 WO 0162227 A2 EP 1257254 A2	22-08-2001 03-09-2001 25-03-2003 30-08-2001 30-08-2001 20-11-2002
WO 0166089	A 13-09-2001	GB 2361869 A AU 3760801 A CA 2402020 A1 CZ 20023017 A3 EP 1280515 A2 WO 0166089 A2 NO 20024222 A AU 7430701 A EP 1296649 A2 WO 0197780 A2	07-11-2001 17-09-2001 13-09-2001 16-04-2003 05-02-2003 13-09-2001 06-11-2002 02-01-2002 02-04-2003 27-12-2001
WO 0174358	A 11-10-2001	AU 5385401 A BG 107185 A BR 0005797 A CA 2403791 A1 CN 1315177 A EP 1265609 A1 NO 20024442 A WO 0174358 A1 US 2002006933 A1	15-10-2001 30-05-2003 16-10-2001 11-10-2001 03-10-2001 18-12-2002 20-11-2002 11-10-2001 17-01-2002